Insulin detemir - Novo Nordisk
Alternative Names: Levemir; Levemir FlexPen; Levemir FlexTouch; LysB29-tetradecanoyl des-(B30) human insulin; NN 304Latest Information Update: 05 Nov 2023
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 27 Sep 2021 BIOCORP and Novo Nordisk enter into a partnership agreement for the use of Mallya technology for FlexTouch pen
- 15 Apr 2021 Discontinued- Phase-III for Type 1 diabetes mellitus (In adolescents, In children, In infants) in Russia, South Africa, Macedonia, Japan (SC) (NCT01513473)
- 15 Apr 2021 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in Brazil, India, Israel, Malaysia, Mexico, Russia, South Korea, Taiwan, Turkey (SC) (NCT02131272)